Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin

Table 1 Baseline characteristics of patients, as a whole and according to final virological response

Characteristics	All n = 113	SVR n = 37	Non SVR n = 76	P1
Male gender (%)	69 (61.1%)	31 (83.8%)	38 (50.0%)	0.0005
Age (mean, yr)	54.1 ± 11.2	50.6 ± 11.1	55.8 ± 10.9	0.02
Alcohol (g/d)				0.4
0	71 (62.8%)	21 (56.8%)	50 (65.8%)
< 20	20 (17.7%)	9 (24.3%)	11 (14.5%)
≥ 20	22 (19.5%)	7 (18.9%)	15 (19.7%)
HCV genotype2				0.0001
1	58 (61.1%)	11 (35.5%)	47 (73.4%)
2	10 (10.5%)	7 (22.6%)	3 (4.7%)
3	15 (15.8%)	8 (25.8%)	7 (10.9%)
4	8 (8.4%)	1 (3.2%)	7 (10.9%)
5	2 (2.1%)	2 (6.5%)	0 (0.0%)
6	2 (2.1%)	2 (6.5%)	0 (0.0%)
Body mass index (kg/m2)	25.9 ± 4.0	24.6 ± 3.8	26.5 ± 4.0	0.015
Platelets (103/mm3)	149.4 ± 56.2	152.9 ± 50.1	147.9 ± 59.2	0.4
Serum albumin (g/L)	43.0 ± 5.0	45.4 ± 6.1	41.8 ± 4.0	0.001
Bilirubin (μmol/L)	14.6 ± 9.6	14.3 ± 7.5	14.8 ± 10.5	0.6
Prothrombin activity (%)	83.7 ± 13.3	84.5 ± 12.6	83.4 ± 13.8	0.7
AFP (ng/mL)	14.4 ± 25.2	8.7 ± 12.9	17.3 ± 29.2	0.008
AST (× ULN)	2.9 ± 2.0	2.4 ± 1.4	3.1 ± 2.3	0.2
ALT (× ULN)	3.1 ± 1.9	3.1 ± 1.9	3.1 ± 2.0	0.7

ULN: Upper limit of normal range; SVR: Sustained virological response. ¹Between SVR and Non-SVR groups;

²Not determinate in 18 patients (15.9%).